388 results about "Inactivated vaccine" patented technology

The invention relates to the technical field of biological agents, in particular to a goose astrovirus egg yolk antibody and a preparation method and application thereof. The invention provides a goose astrovirus egg yolk antibody. The goose astrovirus egg yolk antibody is prepared by adopting an inactivated vaccine as an antigen, wherein the inactivated vaccine is prepared from a goose astrovirus GAstV / SD / 36-95P strain with the preservation number of CCTCC (China Center For Type Culture Collection) NO: V202445. The neutralizing titer of the goose astrovirus egg yolk antibody provided by the invention is high and can reach 10.5 log2, after goslings are infected by the goose astrovirus, the goslings can be protected from disease attack and death by injecting the egg yolk antibody, and the protection rate of the egg yolk antibody can reach 100%.

The invention discloses a chimeric PEDV (porcine epidemic diarrhea virus) infectious clone plasmid, a PEDV chimeric virus as well as a construction method and application thereof. According to the invention, a PEDV genome is used as a skeleton for the first time, the chimeric virus for expressing the extracellular domain of the TGEV S protein is successfully rescued, and it is found that the TCID50 of the chimeric virus for expressing the extracellular domain of the TGEV S protein can be increased by 6.2 times compared with that of the chimeric PEDV for expressing the TGEV S protein. The recombinant virus is used as an inactivated vaccine for immunizing mice, so that the immunogenicity of TGEV S protein can be greatly improved, a body is stimulated to generate a higher-level neutralizing antibody aiming at TGEV, and the titer of the neutralizing antibody aiming at TGEV is improved by 16.8 times. Therefore, more possibilities are provided for modification of viral genomes, a novel method for improving immunogenicity of the TGEV inactivated vaccine is invented, and a basis is provided for research and development of the TGEV vaccine.

The invention provides a bovine parainfluenza virus type 3 QL3 strain, and the preservation number of the bovine parainfluenza virus type 3 QL3 strain is CGMCC No.46469. The invention also provides a bovine parainfluenza inactivated vaccine containing the bovine parainfluenza virus type 3 QL3 strain and purified F protein and HN protein of the QL3 strain. The novel bovine parainfluenza virus type 3 inactivated vaccine is obtained by optimizing the antigen components of the bovine parainfluenza virus type 3 inactivated vaccine, and high-level neutralizing antibodies can be generated after immunizing cattle; the safety of the vaccine is improved through process optimization. Safety and potency test results show that after the inactivated vaccine is used for immunizing cattle, no adverse reaction exists, and high-level neutralizing antibodies are generated. Results show that the immune effect of the bovine parainfluenza virus type 3 inactivated vaccine can be improved.

The invention relates to the technical field of bioengineering, and particularly discloses a chicken infectious anemia virus, a chicken infectious anemia virus egg yolk antibody and a preparation method and application thereof. The invention relates to a chicken infectious anemia virus, which is preserved in the China General Microbiological Culture Collection Center (CGMCC), and is named as the chicken infectious anemia virus RD240101A, the preservation date is September 23, 2024, and the preservation number is CGMCC NO.46198. The chicken infectious anemia virus has the advantages that the chicken infectious anemia virus is named as the chicken infectious anemia virus RD240101A; the chicken infectious anemia virus egg yolk antibody is prepared by taking an inactivated vaccine prepared from the chicken infectious anemia virus RD240101A as an immunogen, is high in specificity and good in safety, does not have any local or whole-body adverse reaction caused by injection of the antibody after being inoculated to chicks, can provide effective immune protection for chicken flocks, and can be used for preparing the chicken infectious anemia virus egg yolk antibody. And the method has a good commercial development prospect.

The invention discloses application of a host factor MOV10 in development of rabies treatment medicines and vaccine production, and belongs to the technical field of biological medicines. In order to research the influence of the host factor MOV10 on the replication of the RABV, the invention discovers that the overexpression host factor MOV10 coding gene can inhibit the replication of the RABV through the technologies of real-time fluorescent quantitative PCR (Polymerase Chain Reaction), Western Blotting, direct immunofluorescence and the like; then, a mov10 gene knockout cell line is successfully constructed through a CRISPR / Cas9 gene editing technology, the cell proliferation activity of the mov10 gene knockout cell line and the influence of the mov10 gene knockout cell line on RABV replication are researched, and it is found that stable knockout of the mov10 gene can remarkably promote replication of RABV CVS11 and SRV9. Technical support is provided for exploration of MOV10 biological functions and development and production of RABV inactivated vaccines and recombinant virus vaccines with RABV as carriers.

The invention provides a larimichthys crocea iridovirus inactivated vaccine as well as a preparation method and application thereof, and belongs to the technical field of preparation of viral vaccines. The larimichthys crocea iridovirus inactivated vaccine comprises an inactivated larimichthys crocea iridovirus and an adjuvant, and the strain of the larimichthys crocea iridovirus is an FD201807 strain. After the larimichthys crocea iridovirus inactivated vaccine is injected, the phenomena of ingestion and abnormal behaviors of fishes are avoided, the death phenomenon is avoided, the safety is high, the relative immune protection rate of the inactivated vaccine to immunized fishes is 51.20% or above, the immune effect is good, and the larimichthys crocea iridovirus inactivated vaccine can be applied to prevention and treatment of larimichthys crocea iridovirus diseases. The preparation method of the larimichthys crocea iridovirus inactivated vaccine is simple and convenient, easy to operate, low in cost and suitable for industrial production.

The invention discloses an H9N2 subtype avian influenza virus, the H9N2 subtype avian influenza virus is A / chick / Guangxi / C1228 / 2015 (H9N2), and the preservation number of the H9N2 subtype avian influenza virus is CGMCC (China General Microbiological Culture Collection Center) No.45222; or the H9N2 subtype avian influenza virus is A / quil / Guangxi / 210Q33 / 2015 (H9N2), and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 46091. The bivalent inactivated vaccine of CK / GX / C1228 / 15 with better antigenicity and the strain QL / GX / 210Q33 / 15 which has better antigenicity and is separated from quails in the live poultry market has a better protection effect on two different branches of H9N2 subtype avian influenza viruses, the lowest immune dose (0.3 mL) can reach the protection rate of 80% or above, and the generated effective protection antibody can last to 24W.

The invention discloses a porcine delta-coronavirus double-antibody sandwich ELISA (enzyme-linked immuno sorbent assay) detection kit based on an S protein monoclonal antibody as well as a use method and application of the porcine delta-coronavirus double-antibody sandwich ELISA detection kit. A PDCoV S protein is expressed by adopting an ExpiCHO expression system, then the purified S protein is used as an immunogen to immunize a mouse, and the monoclonal antibody is obtained. And then, respectively using the monoclonal antibody 3D7 and the MAb 9G4 labeled by the HRP as capture and detection antibodies, and establishing the double-antibody sandwich ELISA kit. The kit has good sensitivity, the detection limit of purified S protein is 0.12 ng / mL, and the detection limit of PDCoV is 1.96 * 10 < 3 > copies / [mu] L. Specificity analysis shows that the kit has no cross reactivity with other porcine intestinal coronaviruses PEDV, TGEV and PoRV with clinical symptoms similar to PDCoV, the consistency with an RT-PCR (reverse transcription-polymerase chain reaction) method reaches 91.03%, and the Kappa value is 0.814, so that the reliability of the kit for clinical sample detection is shown. In addition, the kit can also quantitatively evaluate the content of S protein in PDCoV inactivated vaccines and subunit vaccines, and provides a powerful tool for evaluating the vaccines.

The invention discloses a porcine reproductive and respiratory syndrome virus NADC30 strain SCqq strain, an inactivated vaccine and application, and belongs to the technical field of veterinary medicine. The SCqq strain is preserved in the China Center for Type Culture Collection, the preservation address is Wuhan University, Wuchang District, Wuhan City, Hubei Province, the preservation number is CCTCC NO: V202486, and the preservation time is September 29, 2024. According to the invention, a porcine reproductive and respiratory syndrome virus NADC30 strain SCqq strain is screened, and an inactivated vaccine prepared from the virus strain is high in immunogenicity, safe and reliable, has a very good immune protection effect on porcine reproductive and respiratory syndrome virus NADC30 infection, can induce an organism to generate a high-level antibody, and achieves 100% virulent virus attack protection.

The invention relates to the technical field of biological medicines, in particular to a soluble skin-adhering microneedle for delivering an inactivated enterovirus vaccine as well as a preparation method and application of the soluble skin-adhering microneedle. Sodium hyaluronate is adopted as a film forming material to wrap an enterovirus 71 type (EV71)-coxsackie virus A16 (CA16) type bivalent inactivated vaccine antigen, and a needle body layer of the soluble microneedle is formed; the substrate layer is prepared from a pullulan material, so that the microneedle patch with a stable overall structure is formed. The technology provided by the invention is completed in a clean environment, and the vaccine patch which is qualified through sterility detection is obtained. The soluble microneedle disclosed by the invention has good antigen stability under the condition of 2-8 DEG C. In animal experiments, the microneedle is attached to the skin surface of a mouse for skin-adhering immunization, a strong immune response reaction can be induced, good immunogenicity is shown, and a novel, safe and effective vaccine delivery way is provided for prevention and control of the infantile hand-foot-and-mouth disease.

The invention discloses a 2.3. 4.4b branch H5 subtype avian influenza virus strain and an application thereof. The 2.3. 4.4b branch H5 subtype avian influenza virus strain is an A type avian influenza virus A / chick / Shenyang / 12301 / 2024, is preserved in the China General Microbiological Culture Collection Center (CGMCC), has a preservation number of CGMCC No.46299, and is preserved for December 12, 2024, and the strain has a preservation number of CGMCC No.46299, a preservation number of CGMCC No.46299, a preservation number of CGMCC No.46299 and a preservation number of CGMCC No.46299. According to the invention, 2.3. 4.4b branch H5 subtype AIV with good cross immunoreaction is searched as a vaccine candidate strain to form a whole virus inactivated vaccine, so as to effectively prevent and control the infection of the latest epidemic H5 subtype AIV to poultry, and further eliminate the potential threat of influenza virus to public health safety in poultry breeding.

The invention provides a rabies virus inactivated vaccine and a preparation method thereof, and belongs to the technical field of biological medicines. The invention provides a rabies virus inactivated vaccine. The rabies virus inactivated vaccine comprises an adjuvant and an inactivated VSV-rabies recombinant virus, the inactivated VSV-rabies recombinant virus is obtained by carrying out inactivation on a VSV-rabies recombinant live virus; the VSV-rabies recombinant live virus is prepared by replacing envelope protein G of vesicular stomatitis virus with G protein of rabies virus. The inactivated rabies virus vaccine is good in safety and high in induced antibody level, the immune effect of the inactivated rabies virus vaccine is equivalent to that of a live virus vector vaccine, and the inactivated rabies virus vaccine has a certain application value in the aspect of preventing and controlling rabies.

The invention belongs to the technical field of rabies vaccines, and particularly relates to a purification method of a rabies virus inactivated vaccine, which comprises the following steps: step 1, carrying out passage by using a Walvax-2 cell strain through a cell factory method, and carrying out multiplication culture on the passage production cells in a microcarrier bioreactor; 2, cleaning the cells with a treating fluid, inoculating the cells with a rabies virus fixed strain, and preparing and culturing a rabies virus solution; step 3, carrying out ultrafiltration concentration on the rabies virus stock solution; step 4, purifying the rabies virus concentrated solution; step 5, inactivating the rabies virus; and 6, hydrolyzing to obtain the rabies vaccine stock solution. By adopting the composite Capto Core 700 column chromatography, impure proteins can be effectively removed, the recovery rate is high, the quality of the rabies vaccine obtained by adopting a mode of firstly purifying and then adopting beta-propiolactone inactivation is excellent, and the effect of the finally obtained human diploid cell rabies vaccine stock solution is good.

The invention discloses a recombinant Getai virus for expressing H1N1 subtype swine influenza virus HA protein, the virus has an H1N1 subtype swine influenza virus HA1 protein gene, and the HA1 protein gene is located between E1 and 3 'UTR genes of a Getai virus genome. Accordingly, a corresponding construction method is also established. Furthermore, a corresponding recombinant Geitai virus inactivated vaccine is also developed. Researches show that the inactivated vaccine is used for immunizing mice, can well induce test animals to generate specific antibodies aiming at the H1N1 subtype swine influenza virus, also can generate specific antibodies for expressing the Geitai virus, and provides immune protection for attack of the H1N1 subtype swine influenza virus; and the H1N1 subtype swine influenza virus and Getah virus bivalent inactivated vaccine is successfully prepared. Therefore, the invention has a better effect on prevention and control of the H1N1 subtype swine influenza virus, lays a foundation for the Geitai virus as a carrier to express other exogenous genes, is expected to be used clinically, and can protect a pig farm from being attacked by the two viruses at the same time.

The invention discloses a targeted delivery system of a largemouth bass frog iridovirus oral vaccine and a preparation method of the targeted delivery system, and relates to the technical field of biological medicines.The method comprises the following steps that a starch solution and a largemouth bass frog iridovirus inactivated vaccine are stirred and mixed, then a paraffin emulsion is added, stirring and emulsifying are conducted, and a W / O emulsion is obtained; adding calcium chloride, stirring and mixing, centrifuging, and resuspending by using a PBS (Phosphate Buffer Solution) to obtain a microsphere resuspension solution; stirring and mixing with a quaternized chitosan solution, adding glutaraldehyde for crosslinking, centrifuging, and freeze-drying. The invention further discloses a targeted delivery system of the largemouth bass frog iridovirus oral vaccine prepared by the method. The vaccine is orally administered after being microencapsulated, so that the human cost is low, the stimulation to fish bodies is small, the problems of inconvenience in fish administration, low bioavailability of oral administration, instability in gastrointestinal tracts and the like are solved, and the vaccine has an excellent application prospect in the field of LMBV prevention and control.

The invention discloses a lactobacillus fermentum strain as well as extracellular vesicles and application thereof. The lactobacillus fermentum strain is named as C283, is preserved in the General Microbiological Center of the China Committee for Culture Collection of Microorganisms, and has the microbial preservation number of CGMCC No.30338. The lactobacillus fermentum strain can be used for preparing the lactobacillus fermentum. Researches show that the strain has unique anti-inflammatory and anti-infection dual characteristics, and also has the characteristics of acid resistance, cholate resistance and the like; particularly, the C283 strain can generate extracellular vesicles with very strong immunologic adjuvant activity and immunological enhancement activity, and the C283 strain outer vesicles can directly activate chicken mucous membrane epithelium lymphocytes only through nasal dripping and eye dripping, so that mucous membrane immune response is remarkably enhanced; particularly, the strain exovesicle can be directly used as an efficient mucosal delivery carrier for inactivated viruses or antigens, nucleic acid vaccines or mRNA vaccines, and efficient mucosal immune system delivery of the inactivated vaccines or antigens can be achieved in a mucosal immune mode. The invention provides a new technical means for preparing novel oral vaccines and mucous membrane delivery vaccines.

The present invention relates to the technical field of veterinary biological products, and in particular to a positive serum for a lumpy skin disease virus, and a preparation method therefor and a use thereof. Healthy negative cattle are inoculated with an inactivated vaccine, the number of inoculations is greater than or equal to 2, and the dose of the inactivated vaccine inoculated each time is larger than or equal to 6 mL, so that a positive serum for a lumpy skin disease virus is finally prepared. The positive serum for a lumpy skin disease virus has a neutralizing antibody titer of ≥1:32, and can be fully applicable to each test item involved in the vaccine development process, so that the present invention solves the bottleneck problem of quality control in the development process of inactivated vaccines for lumpy skin diseases, fills the gap in the preparation process of positive serums for a lumpy skin disease virus, and has important significance for long-term development of veterinary biological product industry.

The invention relates to the technical field of inactivated vaccines for poultry, and discloses a bivalent inactivated vaccine composite adjuvant for poultry, which comprises the following components in percentage by mass: 5-10% of nano-scale chitosan microspheres with the particle size range of 50-100 nanometers; the lipidosome is prepared from phospholipid and cholesterol according to the molar ratio of 3: 1, and the mass fraction is 3%-6%; a cell factor interleukin-2 (IL-2) with a concentration of 10 to 20 [mu] g / mL; the mass fraction of the sodium alginate solution is 1%-3%. According to the preparation and application of the bivalent inactivated vaccine composite adjuvant for poultry, the nanoscale chitosan microspheres, the lipidosome and the like are effectively combined through an innovative formula, the nanoscale chitosan microspheres can promote antigen uptake, the lipidosome realizes slow release of the antigen, meanwhile, the cell factor IL-2 activates immune cells, humoral immunity and cellular immunity are comprehensively enhanced, and the immune effect of the bivalent inactivated vaccine composite adjuvant for poultry is improved. The immunogenicity of the vaccine is greatly improved, the organism can be induced to generate higher-level antibodies and stronger cellular immunity, and a defense line is built for the health of poultry.

The invention discloses an akabane virus inactivated vaccine preparation method, which comprises: carrying out Vero cell passage in a cell bottle, taking well growing cells until the cells grow to 80-90%, adding into a DMEM culture medium containing 10% of fetal calf serum, taking out the cells growing to 80-90% and having a good state, adding akabane virus CH-JL-01-2022 according to a volume ratio of 0.1%, and carrying out culture at a temperature of 80-90 DEG C so as to obtain the akabane virus inactivated vaccine. Culturing for 2-3 days in an incubator with the temperature of 37 DEG C and 5% CO2; the method comprises the following steps: preparing 0.25 M BEI, 0.1 M BPL and a 40% formaldehyde solution as inactivators, setting five concentration gradients according to the volume ratios of 0.01%, 0.05%, 0.1% and 0.5%, and collecting after 6 hours, 12 hours, 24 hours, 36 hours and 48 hours after adding; the screening of the akabane virus inactivation conditions according to the types, concentrations and inactivation time of inactivators finds that 0.5% formaldehyde shows a complete inactivation effect after inactivation for 36 hours. The inactivated virus liquid is mixed with MONTANIDETM ISA 201, an ImjectI aluminum adjuvant and a manganese adjuvant according to the volume ratio of 1: 1, and then immunization is carried out, and the protection effect of the ImjectI aluminum adjuvant is found to be optimal.

The invention provides a fish source pseudomonas plecoglossicida, which is preserved in the China Center for Type Culture Collection (CCTCC), and the preservation number is CCTCC M 2024372. The invention also relates to an application of the fish-derived pseudomonas plecoglossicida in preparation of a vaccine for preventing fish visceral white-spot disease. The invention also relates to a vaccine for preventing the fish visceral white-spot disease, which is characterized by comprising the inactivated fish source pseudomonas plecoglossicida. According to the invention, the growth characteristics and toxicity of the separated Pseudomonas plecoglossicida (ND2304 strain) are determined, and the Pseudomonas plecoglossicida (ND2304 strain) is determined to be a virulent strain with strong pathogenicity to large yellow croaker; the prepared corresponding Pseudomonas plecoglossicida inactivated vaccine can be combined with an adjuvant, and the inactivated vaccine is relatively high in safety and relatively high in relative protection rate.

The invention discloses mannheimia haemolytica outer membrane vesicles as well as a preparation method and application thereof, and belongs to the technical field of bioengineering. The OMV is separated from Mh-5 strain culture supernatant through tangential flow ultrafiltration combined with an ultracentrifugation technology, and animal experiments prove that a high-level IgG / IgM antibody can be induced by intramuscular injection of 50 micrograms per mouse, expression of inflammatory factors such as IL-6 and TNF-alpha of the spleen is remarkably improved, the protection rate after challenge reaches 85.7%, and pathological damage is remarkably lighter than that of an inactivated vaccine group. According to the scheme provided by the invention, the problems of insufficient serotype coverage and antibiotic resistance in the prior art are solved, and a new strategy is provided for prevention and control of mannheimia haemolytica.

The invention relates to the technical field of veterinary biological products. The invention provides a poultry epidemic disease inactivated vaccine adjuvant as well as a preparation method and application thereof. The adjuvant is prepared from the following raw materials in dosage ratio: 70 to 80mL of white oil, 0.5 to 1.5 mL of Tween-80, 1 to 2g of chitosan, 0.5 to 1.5 g of astragalus polysaccharide and 0.5 to 1.5 g of vitamin E. According to the invention, multiple raw materials are utilized, and a triple synergistic mechanism of long-acting slow release, efficient activation and safety protection is formed through emulsion stabilization and targeted delivery at a physical level, multi-channel activation (including natural immunity, adaptive immunity, humoral immunity and mucosal immunity) at an immune level and synergistic oxidation resistance and inflammatory reaction regulation at a safety level; the immune response efficiency, the antibody duration and the safety of the vaccine can be remarkably improved, and the vaccine is particularly suitable for the special immune physiological characteristics of poultry.

The invention provides a triple inactivated vaccine for porcine circovirus type 2, porcine mycoplasmal pneumonia and porcine reproductive and respiratory syndrome as well as a preparation method and application of the triple inactivated vaccine, and belongs to the technical field of biology. The triple inactivated vaccine is prepared on the basis of a porcine circovirus type 2 protective antigen Cap protein, a mycoplasma hyopneumoniae protective antigen recombinant fusion protein F-P46-P65 and a porcine reproductive and respiratory syndrome virus PRRSV-NADC30-like LF strain. According to the triple inactivated vaccine, three major diseases caused by the porcine circovirus type 2, the mycoplasma hyopneumoniae and the porcine reproductive and respiratory syndrome virus can be prevented at the same time through one-time inoculation, the immunization procedure is greatly simplified, the stress reaction caused by multiple immunization to pigs is effectively reduced, and the healthy growth of the pigs is guaranteed. The immune cost of a farm is remarkably reduced, the effect of'immune burden reduction 'is really achieved, and the efficiency and economic benefits of breeding management are improved.

The present invention belongs to the technical field of veterinary biological products, and specifically relates to a preparation and usage method of an inactivated vaccine composition for progressive atrophic rhinitis. The inactivated vaccine composition for progressive atrophic rhinitis comprises swine toxigenic Pasteurella multocida (ZXT+Pm), swine Bordetella bronchiseptica (AHBb), N-terminal and C-terminal proteins of toxigenic Pasteurella multocida toxin (PMT) (rPMT-N and rPMT-C) and a carbomer water adjuvant.

The invention discloses a porcine reproductive and respiratory syndrome virus mRNA (messenger Ribonucleic Acid) molecule and application thereof, and four mRNA vaccines GP35m-LNP, GP45m-LNP, GP345m-LNP and GP2345m-LNP are designed by combining structural protein GP2a, GP3, GP4 and GP5 genes of a PRRSV FJ1402 strain of NADC30-like. Mouse test results show that the GP345m-LNP can simultaneously induce strong humoral and cellular immune response, the GP2345m-LNP is secondary, and the effect is superior to that of an inactivated vaccine (only inducing humoral immunity). After immunization, the PRRSV FJ1402 strain is adopted for counteracting toxic substances, the virus load in blood and lungs of a GP345m-LNP group is obviously reduced, pathological injuries of the lungs are obviously relieved, the immune effect is superior to that of an inactivated vaccine group, and the vaccine has a relatively good application prospect.

The invention provides an avian metapneumovirus QL125, the preservation number of which is CGMCC (China General Microbiological Culture Collection Center) No.46219. The invention also provides an application of the avian metapneumovirus QL125 in preparation of an avian metapneumovirus infected animal model and a medicine for preventing and / or treating avian metapneumovirus infection. The invention further provides an avian metapneumovirus vaccine and a preparation method of the avian metapneumovirus vaccine. The avian metapneumovirus vaccine contains the avian metapneumovirus QL125. Experiments prove that after the inactivated vaccine is immunized, a protective antibody is generated quickly, the laying rate of shelducks immunized twice by the inactivated vaccine is basically equal to that of a control group, and the laying rate of laying ducks is effectively prevented from being reduced.

The invention discloses riemerella anatipestifer and application of the riemerella anatipestifer in an egg yolk antibody. The riemerella anatipestifer is named as BRA22A011, and the preservation number of the riemerella anatipestifer is CGMCC (China General Microbiological Culture Collection Center) No.45887. The invention also discloses an inactivated vaccine, wherein the antigen in the inactivated vaccine contains the inactivated riemerella anatipestifer BRA22A011. The invention further discloses an egg yolk antibody, and the egg yolk antibody is prepared by using the riemerella anatipestifer BRA22A011 as an antigen. The use mode of the egg yolk antibody is intramuscular injection inoculation, and the injection dosage is 0.5 mL. The riemerella anatipestifer BRA22A011 has high pathogenicity and strong immunogenicity, and the egg yolk antibody prepared from the riemerella anatipestifer BRA22A011 can replace antibiotics and vaccines, is safe, free of residues, free of drug resistance and environment-friendly, and has a good prospect in clinical application of preventing and treating infectious serositis of ducks. The riemerella anatipestifer BRA22A011 and the Escherichia coli BE-20261 are adopted for preparing the egg yolk antibody together, and the prevention and treatment effects of the egg yolk antibody are more obvious.

The invention relates to circRNA (Ribonucleic Acid) for coding rabies virus as well as a vaccine and application thereof, and belongs to the technical field of biological medicines. The invention relates to circRNA (Ribonucleic Acid) for coding rabies virus. The nucleotide sequence of the circRNA is shown as SEQ ID NO: 1. The circRNA comprises an SRV9 strain rabies virus G protein sequence after coding optimization, the circRNA is delivered through lipid nanoparticles to form the circRNA-LNP vaccine, powerful and lasting body fluid and cellular immune response can be induced in mice and non-human primates, and the complete protection effect can be achieved through a single dose. Compared with a traditional inactivated vaccine, the vaccine has the advantages of being rapid in production, high in heat stability, capable of inducing Th1 type immune bias and the like, is suitable for preventing rabies virus infection and has wide application prospects and popularization value.

The invention discloses a rabies mRNA vaccine and application thereof. The rabies mRNA vaccine takes mRNA of G protein of rabies virus as an active ingredient. The mRNA comprises a coding sequence of a G protein of the rabies virus, and the coding sequence is selected from any one of the following sequences: (1) the G protein comprises an amino acid sequence as shown in SEQ ID NO: 1, and the coding sequence comprises a nucleic acid sequence as shown in any one of SEQ ID NO: 10-14 and 17; and (2) the G protein comprises an amino acid sequence as shown in SEQ ID NO: 8. Compared with the traditional inactivated vaccine, the vaccine provided by the invention has stronger immunogenicity, can stimulate stronger humoral immune response, and has better protection effect.

The application discloses a new Bartonella species DGB1 derived from chicken skin mite and application of the Bartonella species DGB1 in prevention and treatment of chicken skin mite. Bartonella sp. The application provides a new Bartonella species, specifically a Bartonella DGB1, which is registered and listed in the China General Microbiological Culture Collection Center with a registration number of CGMCC No. 36714. The application also provides a Bartonella inactivated bacteria solution and an inactivated vaccine prepared from the Bartonella. The Bartonella inactivated vaccine provided by the application can effectively prevent and control chicken skin mite.